Table 3. SNP’s within VitD regulating enzymes in association with baseline VitD values and VitD variations (ΔVitd) upon antiviral therapy.
Polymorphism | VitD <20 ng/ml | VitD ≥20 ng/ml | p-value | ΔvitD <0 ng/ml | ΔvitD ≥0 ng/ml | p-value |
CYP27B1-rs10877012 (AA/nonAA)1 | 28/205 | 11/122 | 0.2 | 16/151 | 21/141 | 0.3 |
CYP2R1- rs10741657 (AA/nonAA)2 | 30/203 | 21/112 | 0.4 | 23/144 | 18/144 | 0.4 |
DHCR7-rs12785878 (TT vs nonTT)3 | 113/120 | 81/50 | 0.014 | 78/75 | 86/69 | 0.4 |
CYP24A1-rs6013897 (TT vs nonTT)4 | 138/95 | 84/47 | 0.3 | 9/144 | 5/150 | 0.2 |
DHCR7-rs7944926 (GG vs nonGG)5 | 114/119 | 86/45 | 0.002 | 81/72 | 88/67 | 0.4 |
DBP-rs2282679 (TT vs nonTT)6 | 119/114 | 68/61 | 0.7 | 81/72 | 76/79 | 0.4 |
DBP-rs4588 (CC vs nonCC)7 | 112/121 | 67/64 | 0.5 | 77/76 | 70/85 | 0.3 |
DBP-rs7041 (GG vs nonGG)8 | 68/165 | 43/89 | 0.4 | 48/105 | 46/109 | 0.7 |
ΔVitd values were missing in 37 patients, 3–8ΔVitd values were missing in 66 patients.